RNA Sequencing Reveals Unique Transcriptomic Signatures of the Thyroid in a Murine Lung Cancer Model Treated with PD-1 and PD-L1 Antibodies

Article Cell Biology

The Bilateral Interplay between Cancer Immunotherapies and Neutrophils' Phenotypes and Sub-Populations

Naomi Kaisar-Iluz et al.

Summary: Neutrophils are important mediators of immune checkpoint inhibitor treatments, especially normal-density neutrophils that enhance reactive oxygen species production and cytotoxicity towards tumor cells.

CELLS (2022)

Add to Collection

Article Immunology

Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy br

Melissa G. Lechner et al.

Summary: This study identifies the key role of type 3 immune cells, specifically IL-17A-producing T cells, in the development of thyroid immune-related adverse events (IrAEs) associated with immune checkpoint inhibitor (ICI) immunotherapy. Targeting the IL-17A axis effectively reduces the occurrence of thyroid IrAEs without impairing ICI antitumor efficacy.

JOURNAL OF IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors

Joana Lima Ferreira et al.

Summary: Immune-checkpoint inhibitors can lead to thyroid function abnormalities, including primary and central hypothyroidism, which may be predictive of improved clinical outcomes and response to ICI treatment across different types of neoplasms.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Immunology

A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients

Chuan Li et al.

Summary: Single-cell transcriptomics revealed a subset of CD8 T cells with high oxidative phosphorylation in melanoma patients, which correlated with immune checkpoint inhibitor resistance. A predictive model based on transcriptomic profiles of these cells accurately distinguished responders from nonresponders, offering potential as a new target for improving outcomes in melanoma patients.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Add to Collection

Article Endocrinology & Metabolism

Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment

Christopher A. Muir et al.

Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with different subtypes of thyroid immune-related adverse events having unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer progression free survival and overall survival, while hypothyroidism showed no association with cancer outcomes. Multiple distinct phenotypes of thyroid irAEs suggest potentially different etiologies for thyrotoxicosis and hypothyroidism.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

Add to Collection

Article Cell Biology

CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice

Yoshinori Yasuda et al.

Summary: The study found that CD4(+) T cells play a critical role in the development of destructive thyroiditis, and depletion of CD4(+) T cells can completely prevent the occurrence of the disease.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Review Oncology

Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis

Yong Fan et al.

Summary: The occurrence of irAEs is associated with improved tumor response and better survival in cancer patients treated with ICIs, especially in certain cancer types (NSCLC and melanoma) and organ-specific irAEs (skin and endocrine). High grade toxicities were not significantly associated with a favorable PFS or OS. The association between irAEs and clinical benefit appeared to be stronger in patients receiving PD-(L)1 blockade compared to those receiving CTLA-4 blockade.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Endocrinology & Metabolism

Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors

Jee Hee Yoon et al.

Summary: Thyroid immune-related adverse events are common in cancer patients treated with PD-1/PD-L1 inhibitors, with the majority of patients being able to recover normal thyroid function. However, some patients may progress to overt hypothyroidism and require thyroid hormone replacement therapy. Risk factors for developing overt hypothyroidism include higher baseline thyroid stimulating hormone levels and longer duration of therapy.

ENDOCRINOLOGY AND METABOLISM (2021)

Add to Collection

Article Endocrinology & Metabolism

Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment

Christopher A. Muir et al.

Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with distinct phenotypes of thyroid irAEs showing unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer survival outcomes, while no association was found between hypothyroidism and cancer outcomes.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

Add to Collection

Article Endocrinology & Metabolism